Given its involvement in both metabolic adaptation and immune modulation, targeting DDX3 may offer a promising strategy for combination therapies aimed at overcoming the dual challenges of metastasis and therapeutic resistance in breast cancer. This evidence concerns the gene DDX3X and breast carcinoma.